Profiles

Guei-Sheung Liu

UTAS Home Dr Guei-Sheung (Rick) Liu
Rick Liu

Guei-Sheung (Rick) Liu

Senior Research Fellow

Medical Science 2 , Hobart CBD Campuses

(03) 6226 7700 (phone)

GueiSheung.Liu@utas.edu.au

Dr Guei-Sheung Liu is a Senior Research Fellow, a group leader of genetic engineering research at the Menzies Institute for Medical Research of the University of Tasmania, and adjunct Principal Investigator of Ophthalmology at Jinan University (China) as well as an Honorary Senior Fellow at the University of Melbourne (Ophthalmology, Department of Surgery). Dr Liu is interested in the field of genetic engineering and ocular gene therapy.

Biography

Dr Liu received his PhD in biochemistry and molecular biology in 2006 from the Kaohsiung Medical University (Kaohsiung, Taiwan) working on the development of gene therapy for targeting neovascularization and neuroprotection. For over ten years, Dr Liu has contributed to the design, development, and evaluation of innovative gene therapy approaches to prevent and delay blindness of major eye diseases. After joined the Menzies, Dr Liu’s work has extended from traditional gene therapy into the fields of genome editing, and a major focus of his ongoing work is to refine these applications to clear the hurdles impeding clinical translation. Moreover, his group also interests in the application of next-generation sequencing technologies for understanding common, complex as well as rare ‘orphan’ ocular diseases. To date, Dr Liu’s research has led to 59 publications (42 from last five years, >50% first/senior author). He is also an editorial board member of two international journals (PLoS ONE and Journal of Gene Medicine).

Career summary

Qualifications

  • PhD, Kaohsiung Medical University, Taiwan, 2006

Languages (other than English)

Mandarin

Memberships

Professional practice

Member, Association for Research in Vision and Ophthalmology, USA (2013 - current)

Member, the American Society of Gene & Cell Therapy, USA (2008 - current)

Member, Australasian Gene Therapy Society, Australia (2014 - current)

Member, Tissue Engineering and Regenerative Medicine International Society (2009 - current)

Committee associations

Organising committee for TERMIS-AP annual conference, 2014 and 2016

American Society of Gene & Cell Therapy abstract review committee, 2017

Other

Dr Liu currently serves on the editorial board of PLoS One (the world's first multidisciplinary Open Access journal) and Journal of Gene Medicine (official journal of Australasian Gene and Cell Therapy Society). He has also undertaken extensive peer review for over 30 international journals as well as is frequently invited to review conference abstracts and judge for conference posters/oral presentations (Biomed Link and the American Society of Gene & Cell Therapy Annual Meeting).

Research Invitations

Over last five years, Dr Liu has given talks at 13 International and 4 national conferences including 2 invited keynote speeches at International Symposium of Materials on Regenerative Medicine (ISOMRM, Taoyuan, 2017), and Tissue Engineering and Regenerative Medicine International Society-Asia Pacific Conference (Taipei, 2016); 6 invited speaker at Asia-Pacific Academy of Ophthalmology Conference (2017 and 2019), International Forum of Ophthalmology in Taipei Medical University (Taipei, 2017), the Tasmania branch Meeting of the RANZCO Genetics Meeting (Hobart, 2016), International ANZ-Taiwan Symposium of biomaterial (Taipei, 2015) and Neurotalk conference (Beijing, 2013).

View more on Dr Guei-Sheung Liu in WARP

Expertise

Genetic engineering

Gene therapy for ocular disease

Research Themes

Dr Liu’s research aligns with one of the University's key research themes of Better Health. Research in his group is aiming at clearing hurdles impeding the clinical translation of ocular gene therapies, in particular therapeutic delivery, where he has recently transitioned from traditional “gene therapy” to “genome editing” technologies. With these optimized technologies, the aim is to partake and lead gene therapies for blindness in the clinic. He has recently conducted notable research in ocular gene therapy and genome editing for ocular neovascularisation and retinal diseases. Moreover, Dr Liu’s group also interests in the application of next-generation sequencing technologies for understanding common, complex as well as rare ‘orphan’ ocular diseases.

Collaboration

Dr Liu maintains strong and productive research collaborations both nationally and internationally, including with researchers at University of Melbourne, Monash University, Centre for Eye Research Australia, Children's Medical Research Institute, Lion Eye Research Institute, St Vincent's Institute of Medical Research, Bionics Institute, Singapore Eye Research Institute, University of Utah, National Sun Yat-sen University, Taipei Medical University, I-Suo University, Jinan University and Shenzhen Eye Hospital.

Awards

CASS Travel Award, CASS Foundation, 2014

ZOC/SKLO Travel Award, Zhongshan Ophthalmic Center and the State Key Laboratory of Ophthalmology, 2013

Harold Mitchell Travel Award, Harold Mitchell Foundation, 2012

Young Investigator Award, the 2nd International Symposium of Materials on Regenerated Medicine, 2012

Current projects

Research Project:

  1. Utility of CRISPR/Cas-based Gene Therapy for Preventing Neovascular Blindness
  2. Construction of A Single-cell Transcriptomics Atlas for Diabetic Retinopathy
  3. Targeting Dysregulated miRNAs to Stop the Growth of Blood Vessels in Diabetic Eyes

Fields of Research

  • Gene and Molecular Therapy (100401)
  • Ophthalmology (111301)
  • Cancer Genetics (111203)
  • Gene Expression (incl. Microarray and other genome-wide approaches) (060405)
  • Molecular Targets (111207)
  • Cellular Nervous System (110902)
  • Cell Development, Proliferation and Death (060103)
  • Animal Immunology (060804)
  • Central Nervous System (110903)
  • Cancer Cell Biology (111201)
  • Biomaterials (090301)
  • Vision Science (111303)
  • Otorhinolaryngology (110315)
  • Regenerative Medicine (incl. Stem Cells and Tissue Engineering) (100404)
  • Genomics (060408)
  • Biochemistry and Cell Biology (060199)
  • Infectious Agents (060502)
  • Infectious Diseases (110309)
  • Conservation and Biodiversity (050202)
  • Veterinary Immunology (070705)
  • Aboriginal and Torres Strait Islander Health (111701)
  • Genetics (060499)

Research Objectives

  • Inherited Diseases (incl. Gene Therapy) (920110)
  • Hearing, Vision, Speech and Their Disorders (920107)
  • Diabetes (920104)
  • Cancer and Related Disorders (920102)
  • Expanding Knowledge in the Medical and Health Sciences (970111)
  • Neurodegenerative Disorders Related to Ageing (920112)
  • Urogenital System and Disorders (920119)
  • Cardiovascular System and Diseases (920103)
  • Flora, Fauna and Biodiversity at Regional or Larger Scales (960805)
  • Expanding Knowledge in the Biological Sciences (970106)
  • Nervous System and Disorders (920111)
  • Immune System and Allergy (920108)
  • Veterinary Biological Preventatives (e.g. Vaccines) (860901)
  • Infectious Diseases (920109)
  • Disease Distribution and Transmission (incl. Surveillance and Response) (920404)
  • Control of Animal Pests, Diseases and Exotic Species in Forest and Woodlands Environments (960404)

Publications

To date, Dr Liu’s research has published 46 original research publications, as well as 9 review articles and 3 invited book chapters. These papers are published in leading journals (top 10% in the subject field), including Stem Cells, Redox Biology, and Antioxidants & Redox Signaling, as well as in the high-inference journals in my field including Human Gene Therapy (x4), Molecular Therapy-Methods & Clinical Development (x1), Investigative Ophthalmology & Visual Science (x3), and Free Radical Biology Medicine (x2). As recognised in the field of ophthalmology and gene therapy research, he was invited to write the expert reviews in leading journals, including Pharmacology & Therapeutics as well as Progress in Retinal and Eye Research (top-ranked in ophthalmology).

Dr Liu currently serves on the editorial boards of two international journals, PLoS One (the world's first multidisciplinary Open Access journal) and Journal of Gene Medicine (official journal of Australasian Gene and Cell Therapy Society). He is also actively engaged in the peer review process as an ad hoc reviewer for more than 30 international journals.

Total publications

56

Journal Article

(54 outputs)
YearCitationAltmetrics
2020Flies AS, Flies EJ, Fox S, Gilbert A, Johnson SR, et al., 'An oral bait vaccination approach for the Tasmanian devil facial tumor diseases', Expert Review of Vaccines, 19, (1) pp. 1-10. ISSN 1476-0584 (2020) [Refereed Article]

DOI: 10.1080/14760584.2020.1711058 [eCite] [Details]

Co-authors: Flies AS; Flies EJ; Lyons AB; Patchett AL; Pye RJ

Tweet

2019Chuang Y-L, Fang H-W, Ajitsaria A, Chen K-H, Su C-Y, et al., 'Development of kaempferol-loaded gelatin nanoparticles for the treatment of corneal neovascularization in mice', Pharmaceutics, 11, (12) Article 635. ISSN 1999-4923 (2019) [Refereed Article]

DOI: 10.3390/pharmaceutics11120635 [eCite] [Details]

Tweet

2019Li F, Hung SSC, Mohd Khalid MKN, Wang J-H, Chrysostomou V, et al., 'Utility of self-destructing CRISPR/Cas constructs for targeted gene editing in the retina', Human Gene Therapy, 30, (11) pp. 1349-1360. ISSN 1043-0342 (2019) [Refereed Article]

DOI: 10.1089/hum.2019.021 [eCite] [Details]

Citations: Scopus - 4Web of Science - 2

Co-authors: Wing K; Bender JA; King AE; Cook AL; Hewitt AW

Tweet

2019Nguyen Tran MT, Mohd Khalid MKN, Pebay A, Cook AL, Liang HH, et al., 'Screening of CRISPR/Cas base editors to target the AMD high-risk Y402H complement factor H variant', Molecular Vision, 25 pp. 174-182. ISSN 1090-0535 (2019) [Refereed Article]

PMID: 30996586 [eCite] [Details]

Co-authors: Cook AL; Hewitt AW

Tweet

2019Wu J-C, Tsai H-E, Liu G-S, Wu C-S, Tai M-H, 'Autophagic cell death participates in POMC-induced melanoma suppression', Cell Death Discovery, 5 Article 11. ISSN 2058-7716 (2019) [Refereed Article]

DOI: 10.1038/s41420-018-0070-5 [eCite] [Details]

Citations: Web of Science - 4

Tweet

2018Bee Y-S, Ma Y-L, Chen J, Tsai P-J, Sheu S-J, et al., 'Inhibition of experimental choroidal neovascularization by a novel peptide derived from calreticulin anti-angiogenic domain', International Journal of Molecular Sciences, 19, (10) Article 2993. ISSN 1422-0067 (2018) [Refereed Article]

DOI: 10.3390/ijms19102993 [eCite] [Details]

Citations: Scopus - 1Web of Science - 2

Co-authors: Chen J

Tweet

2018Ding Y, Chow SH, Liu G-S, Wang B, Lin T-W, et al., 'Annexin V-containing cubosomes for targeted early detection of apoptosis in degenerative retinal tissue', Journal of Materials Chemistry B, 6, (46) pp. 7652-7661. ISSN 2050-750X (2018) [Refereed Article]

DOI: 10.1039/c8tb02465k [eCite] [Details]

Citations: Scopus - 4Web of Science - 3

Tweet

2018Hoque A, Sivakumaran P, Bond ST, Ling NXY, Kong AM, et al., 'Mitochondrial fission protein Drp1 inhibition promotes cardiac mesodermal differentiation of human pluripotent stem cells', Cell Death Discovery, 4 Article 39. ISSN 2058-7716 (2018) [Refereed Article]

DOI: 10.1038/s41420-018-0042-9 [eCite] [Details]

Citations: Scopus - 17Web of Science - 13

Tweet

2018Lee JH, Wang J-H, Chen J, Li F, Edwards TL, et al., 'Gene therapy for visual loss: opportunities and concerns', Progress in Retinal and Eye Research, 68 pp. 31-53. ISSN 1350-9462 (2018) [Refereed Article]

DOI: 10.1016/j.preteyeres.2018.08.003 [eCite] [Details]

Citations: Scopus - 15Web of Science - 10

Co-authors: Hewitt AW

Tweet

2018Saddala MS, Lennikov A, Grab DJ, Liu G-S, Tang S, et al., 'Proteomics reveals ablation of PlGF increases antioxidant and neuroprotective proteins in the diabetic mouse retina', Scientific Reports, 8, (1) Article 16728. ISSN 2045-2322 (2018) [Refereed Article]

DOI: 10.1038/s41598-018-34955-x [eCite] [Details]

Citations: Scopus - 4Web of Science - 6

Tweet

2018Tsai C-H, Wang P-Y, Lin I-C, Huang H, Liu G-S, et al., 'Ocular drug delivery: role of degradable polymeric nanocarriers for ophthalmic application', International Journal of Molecular Sciences, 19, (9) Article 2830. ISSN 1422-0067 (2018) [Refereed Article]

DOI: 10.3390/ijms19092830 [eCite] [Details]

Citations: Scopus - 22Web of Science - 17

Tweet

2018Tu L, Wang J-H, Barathi VA, Prea SM, He Z, et al., 'AAV-mediated gene delivery of the calreticulin anti-angiogenic domain inhibits ocular neovascularization', Angiogenesis, 21, (1) pp. 95-109. ISSN 0969-6970 (2018) [Refereed Article]

DOI: 10.1007/s10456-017-9591-4 [eCite] [Details]

Citations: Scopus - 4Web of Science - 4

Co-authors: Bender J; King AE

Tweet

2017Bee Y-S, Tu L, Sheu S-J, Lin H-C, Tang J-H, et al., 'Gene delivery of calreticulin anti-angiogenic domain attenuates the development of choroidal neovascularization in rats', Human Gene Therapy, 28, (5) pp. 403-414. ISSN 1043-0342 (2017) [Refereed Article]

DOI: 10.1089/hum.2016.035 [eCite] [Details]

Citations: Scopus - 2Web of Science - 1

Tweet

2017Brown KD, Shah MH, Liu G-S, Chan E, Crowston JG, et al., 'Transforming growth factor β1-induced NADPH Oxidase-4 expression and fibrotic response in conjunctival fibroblasts', Investigative Ophthalmology & Visual Science, 58, (7) pp. 3011-3017. ISSN 1552-5783 (2017) [Refereed Article]

DOI: 10.1167/iovs.16-20633 [eCite] [Details]

Citations: Scopus - 8Web of Science - 7

Tweet

2017Chang CY, Wang MC, Miyagawa T, Chen ZY, Lin FH, et al., 'Preparation of arginine-glycine-aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization', International Journal of Nanomedicine, 12 pp. 279-294. ISSN 1178-2013 (2017) [Refereed Article]

DOI: 10.2147/IJN.S114754 [eCite] [Details]

Citations: Scopus - 12Web of Science - 9

Tweet

2017Wang J-H, Ling D, Tu L, van Wijngaarden P, Dusting GJ, et al., 'Gene therapy for diabetic retinopathy: are we ready to make the leap from bench to bedside?', Pharmacology and Therapeutics, 173 pp. 1-18. ISSN 0163-7258 (2017) [Refereed Article]

DOI: 10.1016/j.pharmthera.2017.01.003 [eCite] [Details]

Citations: Scopus - 12Web of Science - 10

Tweet

2017Wang J-H, Wang R, Lee JH, Iao TWU, Hu X, et al., 'Public attitudes toward gene therapy in China', Molecular Therapy - Methods & Clinical Development, 6 pp. 40-42. ISSN 2329-0501 (2017) [Letter or Note in Journal]

DOI: 10.1016/j.omtm.2017.05.008 [eCite] [Details]

Citations: Scopus - 5Web of Science - 5

Tweet

2016Chan EC, Kuo SM, Kong AM, Morrison WA, Dusting GJ, et al., 'Three Dimensional Collagen Scaffold Promotes Intrinsic Vascularisation for Tissue Engineering Applications', PLoS One, 11, (2) Article e0149799. ISSN 1932-6203 (2016) [Refereed Article]

DOI: 10.1371/journal.pone.0149799 [eCite] [Details]

Citations: Scopus - 55Web of Science - 54

Tweet

2016Chan EC, van Wijngaarden P, Chan E, Ngo D, Wang JH, et al., 'NADPH oxidase 2 plays a role in experimental corneal neovascularization', Clinical Science, 130, (9) pp. 683-696. ISSN 0143-5221 (2016) [Refereed Article]

DOI: 10.1042/CS20150103 [eCite] [Details]

Citations: Scopus - 5Web of Science - 6

Tweet

2016Hung SSC, Chrysostomou V, Li F, Lim JKH, Wang J-H, et al., 'AAV-mediated CRISPR/Cas gene editing of retinal cells in vivo', Investigative Ophthalmology & Visual Science, 57, (7) pp. 3470-3476. ISSN 1552-5783 (2016) [Refereed Article]

DOI: 10.1167/iovs.16-19316 [eCite] [Details]

Citations: Scopus - 62Web of Science - 53

Co-authors: King AE; Hewitt AW

Tweet

2016Liu GS, Peshavariya HM, Higuchi M, Chan EC, Dusting GJ, et al., 'Pharmacological priming of adipose-derived stem cells for paracrine VEGF production with deferoxamine', Journal of Tissue Engineering and Regenerative Medicine, 10, (3) pp. E167-E176. ISSN 1932-6254 (2016) [Refereed Article]

DOI: 10.1002/term.1796 [eCite] [Details]

Citations: Scopus - 13Web of Science - 14

Tweet

2016Shen HH, Liu GS, Chow SH, Wang JH, He Z, et al., 'Intraocular Pressure Induced Retinal Changes Identified Using Synchrotron Infrared Microscopy', PLoS One, 11, (10) Article e0164035. ISSN 1932-6203 (2016) [Refereed Article]

DOI: 10.1371/journal.pone.0164035 [eCite] [Details]

Citations: Scopus - 5Web of Science - 4

Tweet

2016Zhao J, Zhu TH, Chen WC, Peng SM, Huang XS, et al., 'Optic neuropathy and increased retinal glial fibrillary acidic protein due to microbead-induced ocular hypertension in the rabbit', International Journal of Ophthalmology, 9, (12) pp. 1732-1739. ISSN 2222-3959 (2016) [Refereed Article]

DOI: 10.18240/ijo.2016.12.05 [eCite] [Details]

Citations: Web of Science - 2

Tweet

2015Chan EC, Liu G, Dusting GJ, 'Redox mechanisms in pathological angiogenesis in the retina: roles for NADPH oxidase', Current Pharmaceutical Design, 21, (41) pp. 5988-5998. ISSN 1381-6128 (2015) [Refereed Article]

DOI: 10.2174/1381612821666151029111127 [eCite] [Details]

Citations: Scopus - 10Web of Science - 10

Tweet

2015Liu GS, Wang JH, Lee JH, Tsai PJ, Tsai HE, et al., 'Gene delivery by subconjunctival injection of adenovirus in rats: A study of local distribution, transgene duration and safety', PLoS One, 10, (12) Article e0143956. ISSN 1932-6203 (2015) [Refereed Article]

DOI: 10.1371/journal.pone.0143956 [eCite] [Details]

Citations: Scopus - 9Web of Science - 4

Tweet

2015Liu J, Bi X, Chen T, Zhang Q, Wang SX, et al., 'Shear stress regulates endothelial cell autophagy via redox regulation and Sirt1 expression', Cell Death & Disease, 6 Article e1827. ISSN 2041-4889 (2015) [Refereed Article]

DOI: 10.1038/cddis.2015.193 [eCite] [Details]

Citations: Scopus - 57Web of Science - 56

Tweet

2015Lu J, Le Brun AP, Chow SH, Shiota T, Wang B, et al., 'Defining the structural characteristics of annexin V binding to a mimetic apoptotic membrane', European Biophysics Journal, 44, (8) pp. 697-708. ISSN 0175-7571 (2015) [Refereed Article]

DOI: 10.1007/s00249-015-1068-z [eCite] [Details]

Citations: Scopus - 5Web of Science - 4

Tweet

2015Prea SM, Chan EC, Dusting GJ, Vingrys AJ, Bui BV, et al., 'Gene therapy with endogenous inhibitors of angiogenesis for neovascular age-related macular degeneration: Beyond anti-VEGF therapy', Journal of Ophthalmology, 2015 Article 201726. ISSN 2090-004X (2015) [Refereed Article]

DOI: 10.1155/2015/201726 [eCite] [Details]

Citations: Scopus - 15Web of Science - 12

Tweet

2015Shah MH, Liu GS, Thompson EW, Dusting GJ, Peshavariya HM, 'Differential effects of superoxide dismutase and superoxide dismutase/catalase mimetics on human breast cancer cells', Breast Cancer Research and Treatment, 150, (3) pp. 523-534. ISSN 0167-6806 (2015) [Refereed Article]

DOI: 10.1007/s10549-015-3329-z [eCite] [Details]

Citations: Scopus - 12Web of Science - 10

Tweet

2015Shen HH, Chan EC, Lee JH, Bee YS, Lin TW, et al., 'Nanocarriers for treatment of ocular neovascularization in the back of the eye: new vehicles for ophthalmic drug delivery', Nanomedicine, 10, (13) pp. 2093-2107. ISSN 1743-5889 (2015) [Refereed Article]

DOI: 10.2217/nnm.15.47 [eCite] [Details]

Citations: Scopus - 17Web of Science - 12

Tweet

2015Zhang Y, Sivakumaran P, Newcomb AE, Hernandez D, Harris N, et al., 'Cardiac Repair With a Novel Population of Mesenchymal Stem Cells Resident in the Human Heart', Stem Cell, 33, (10) pp. 3100-3113. ISSN 1945-4570 (2015) [Refereed Article]

DOI: 10.1002/stem.2101 [eCite] [Details]

Citations: Scopus - 30Web of Science - 28

Co-authors: Hewitt AW

Tweet

2014Chan EC, Dusting GJ, Liu GS, Jiang F, 'Redox mechanisms of the beneficial effects of heme oxygenase in hypertension', Journal of Hypertension, 32, (7) pp. 1379-1386. ISSN 0263-6352 (2014) [Refereed Article]

DOI: 10.1097/HJH.0000000000000179 [eCite] [Details]

Citations: Scopus - 13Web of Science - 13

Tweet

2014Jiang F, Liu GS, Dusting GJ, Chan EC, 'NADPH oxidase-dependent redox signaling in TGF-β-mediated fibrotic responses', Redox Biology, 2 pp. 267-272. ISSN 2213-2317 (2014) [Refereed Article]

DOI: 10.1016/j.redox.2014.01.012 [eCite] [Details]

Citations: Scopus - 124Web of Science - 119

Tweet

2014Liu GS, Wu JC, Tsai HE, Dusting GJ, Chan EC, et al., 'Proopiomelanocortin gene delivery induces apoptosis in melanoma through NADPH oxidase 4-mediated ROS generation', Free Radical Biology and Medicine, 70 pp. 14-22. ISSN 0891-5849 (2014) [Refereed Article]

DOI: 10.1016/j.freeradbiomed.2013.12.024 [eCite] [Details]

Citations: Scopus - 9Web of Science - 9

Tweet

2014Peshavariya HM, Chan EC, Liu GS, Jiang F, Dusting GJ, 'Transforming growth factor-β1 requires NADPH oxidase 4 for angiogenesis in vitro and in vivo', Journal of Cellular and Molecular Medicine, 18, (6) pp. 1172-1183. ISSN 1582-1838 (2014) [Refereed Article]

DOI: 10.1111/jcmm.12263 [eCite] [Details]

Citations: Scopus - 29Web of Science - 28

Tweet

2014Peshavariya HM, Liu GS, Chang CWT, Jiang F, Chan EC, et al., 'Prostacyclin signaling boosts NADPH oxidase 4 in the endothelium promoting cytoprotection and angiogenesis', Antioxidants and Redox Signaling, 20, (17) pp. 2710-2725. ISSN 1523-0864 (2014) [Refereed Article]

DOI: 10.1089/ars.2013.5374 [eCite] [Details]

Citations: Scopus - 20Web of Science - 19

Tweet

2014Zhang H, Brown KD, Lowe SP, Liu GS, Steele D, et al., 'Acrylic acid surface-modified contact lens for the culture of limbal stem cells', Tissue Engineering. Part A, 20, (11-12) pp. 1593-1602. ISSN 1937-3341 (2014) [Refereed Article]

DOI: 10.1089/ten.TEA.2013.0320 [eCite] [Details]

Citations: Scopus - 7Web of Science - 7

Tweet

2013Chan EC, Peshavariya HM, Liu GS, Jiang F, Lim SY, et al., 'Nox4 modulates collagen production stimulated by transforming growth factor β1 in vivo and in vitro', Biochemical and Biophysical Research Communications, 430, (3) pp. 918-925. ISSN 0006-291X (2013) [Refereed Article]

DOI: 10.1016/j.bbrc.2012.11.138 [eCite] [Details]

Citations: Scopus - 42Web of Science - 37

Tweet

2013Chan EC, Tai MH, Wu PC, Kuo HM, Jiang F, et al., 'Expression of the proangiogenic protein hepatoma-derived growth factor in neovessels in an arterial venous loop-based tissue engineering chamber', Biomedical Engineering: Applications, Basis and Communications, 25, (5) Article 1340007. ISSN 1793-7132 (2013) [Refereed Article]

DOI: 10.4015/S1016237213400073 [eCite] [Details]

Tweet

2013Chan EC, van Wijngaarden P, Liu GS, Jiang F, Peshavariya H, et al., 'Involvement of Nox2 NADPH oxidase in retinal neovascularization', Investigative Ophthalmology and Visual Science, 54, (10) pp. 7061-7067. ISSN 0146-0404 (2013) [Refereed Article]

DOI: 10.1167/iovs.13-12883 [eCite] [Details]

Citations: Scopus - 35Web of Science - 34

Tweet

2013Higuchi M, Dusting GJ, Peshavariya H, Jiang F, Hsiao STF, et al., 'Differentiation of human adipose-derived stem cells into fat involves reactive oxygen species and Forkhead Box O1 mediated upregulation of antioxidant enzymes', Stem Cells and Development, 22, (6) pp. 878-888. ISSN 1547-3287 (2013) [Refereed Article]

DOI: 10.1089/scd.2012.0306 [eCite] [Details]

Citations: Scopus - 100Web of Science - 94

Tweet

2013Peshavariya HM, Taylor CJ, Goh C, Liu GS, Jiang F, et al., 'Annexin peptide Ac2-26 suppresses TNFα-induced inflammatory responses via inhibition of Rac1-dependent NADPH oxidase in human endothelial cells', PLoS One, 8, (4) Article e60790. ISSN 1932-6203 (2013) [Refereed Article]

DOI: 10.1371/journal.pone.0060790 [eCite] [Details]

Citations: Scopus - 24Web of Science - 25

Tweet

2013Tsai HE, Liu GS, Kung ML, Liu LF, Wu JC, et al., 'Downregulation of hepatoma-derived growth factor contributes to retarded lung metastasis via inhibition of epithelial-mesenchymal transition by systemic POMC gene delivery in melanoma', Molecular Cancer Therapeutics, 12, (6) pp. 1016-1025. ISSN 1535-7163 (2013) [Refereed Article]

DOI: 10.1158/1535-7163.MCT-12-0832 [eCite] [Details]

Citations: Scopus - 19Web of Science - 17

Tweet

2013Tsai HE, Wu JC, Kung ML, Liu LF, Kuo LH, et al., 'Up-regulation of hepatoma-derived growth factor facilitates tumor progression in malignant melanoma', PLoS One, 8, (3) Article e59345. ISSN 1932-6203 (2013) [Refereed Article]

DOI: 10.1371/journal.pone.0059345 [eCite] [Details]

Citations: Scopus - 12Web of Science - 11

Tweet

2012Chen CH, Kuo SM, Liu GS, Chen WNU, Chuang CW, et al., 'Enhancement of neurite outgrowth in neuron cancer stem cells on 3-D collagen scaffolds', Biochemical and Biophysical Research Communications, 428, (1) pp. 68-73. ISSN 1090-2104 (2012) [Refereed Article]

DOI: 10.1016/j.bbrc.2012.10.007 [eCite] [Details]

Citations: Scopus - 7Web of Science - 6

Tweet

2012Hsu SS, Chen CH, Liu GS, Tai MH, Wang JS, et al., 'Tumorigenesis and prognostic role of hepatoma-derived growth factor in human gliomas', Journal of Neuro-Oncology, 107, (1) pp. 101-109. ISSN 0167-594X (2012) [Refereed Article]

DOI: 10.1007/s11060-011-0733-z [eCite] [Details]

Citations: Scopus - 24Web of Science - 23

Tweet

2012Kung ML, Tsai HE, Hu TS, Kuo HM, Liu LF, et al., 'Hepatoma-derived growth factor stimulates podosome rosettes formation in NIH/3T3 cells through the activation of phosphatidylinositol 3-kinase/Akt pathway', Biochemical and Biophysical Research Communications, 425, (2) pp. 169-176. ISSN 1090-2104 (2012) [Refereed Article]

DOI: 10.1016/j.bbrc.2012.07.060 [eCite] [Details]

Citations: Scopus - 16Web of Science - 17

Tweet

2012Liu GS, Chan EC, Higuchi M, Dusting GJ, Jiang F, 'Redox mechanisms in regulation of adipocyte differentiation: beyond a general stress response', Cells, 1, (4) pp. 976-993. ISSN 2073-4409 (2012) [Refereed Article]

DOI: 10.3390/cells1040976 [eCite] [Details]

Tweet

2012Liu GS, Peshavariya H, Higuchi M, Brewer AC, Chang CW, et al., 'Microphthalmia-associated transcription factor modulates expression of NADPH oxidase type 4: a negative regulator of melanogenesis', Free Radical Biology and Medicine, 52, (9) pp. 1835-1843. ISSN 0891-5849 (2012) [Refereed Article]

DOI: 10.1016/j.freeradbiomed.2012.02.040 [eCite] [Details]

Citations: Scopus - 18Web of Science - 17

Tweet

2012Tee R, Morrison WA, Dusting GJ, Liu GS, Choi YS, et al., 'Transplantation of engineered cardiac muscle flaps in syngeneic rats', Tissue Engineering: Part A, 18, (19-20) pp. 1992-1999. ISSN 1937-3341 (2012) [Refereed Article]

DOI: 10.1089/ten.TEA.2012.0151 [eCite] [Details]

Citations: Scopus - 34Web of Science - 36

Tweet

2012Tsai HE, Liu LF, Dusting GJ, Weng WT, Chen SC, et al., 'Pro-opiomelanocortin gene delivery suppresses the growth of established Lewis lung carcinoma through a melanocortin-1 receptor-independent pathway', Journal of Gene Medicine, 14, (1) pp. 44-53. ISSN 1099-498X (2012) [Refereed Article]

DOI: 10.1002/jgm.1625 [eCite] [Details]

Citations: Scopus - 10Web of Science - 9

Tweet

2011Liu GS, Tsai HE, Weng WT, Liu LF, Weng CH, et al., 'Systemic pro-opiomelanocortin expression induces melanogenic differentiation and inhibits tumor angiogenesis in established mouse melanoma', Human Gene Therapy, 22, (3) pp. 325-335. ISSN 1043-0342 (2011) [Refereed Article]

DOI: 10.1089/hum.2010.090 [eCite] [Details]

Citations: Scopus - 22Web of Science - 20

Tweet

2011Shen PC, Shiau AL, Jou IM, Lee CH, Tai MH, et al., 'Inhibition of cartilage damage by pro-opiomelanocortin prohormone overexpression in a rat model of osteoarthritis', Experimental Biology and Medicine, 236, (3) pp. 334-340. ISSN 1535-3702 (2011) [Refereed Article]

DOI: 10.1258/ebm.2010.010319 [eCite] [Details]

Citations: Scopus - 17Web of Science - 15

Tweet

2011Shi JY, Liu GS, Liu LF, Kuo SM, Ton CH, et al., 'Glial cell line-derived neurotrophic factor gene transfer exerts protective effect on axons in sciatic nerve following constriction-induced peripheral nerve injury', Human Gene Therapy, 22, (6) pp. 721-731. ISSN 1043-0342 (2011) [Refereed Article]

DOI: 10.1089/hum.2010.036 [eCite] [Details]

Citations: Scopus - 22Web of Science - 22

Tweet

Chapter in Book

(2 outputs)
YearCitationAltmetrics
2019Wang J-H, Chen J, Kuo S-M, Mitchell GM, Lim SY, et al., 'Methods for assessing scaffold vascularization in vivo', Skin Tissue Engineering: Methods and Protocols, Methods in Molecular Biology, Humana Press, S Bottcher-Haberzeth and T Biedermann (ed), pp. 217-226. ISBN 978-1-4939-9472-4 (2019) [Other Book Chapter]

DOI: 10.1007/978-1-4939-9473-1 [eCite] [Details]

Tweet

2018Hung SS, Li F, Wang J-H, King AE, Bui BV, et al., 'Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina', Retinal Gene Therapy: Methods and Protocols, Humana Press, CJF Boon, J Wijnholds (ed), United States, pp. 113-133. ISBN 978-1-4939-7521-1 (2018) [Other Book Chapter]

DOI: 10.1007/978-1-4939-7522-8_9 [eCite] [Details]

Citations: Scopus - 2

Co-authors: King AE

Tweet

Grants & Funding

Since 2013, Dr Liu has received considerable national and international research funding (~AU$2M) primarily from the NH&MRC (3x), Ophthalmic Research Institute of Australia (3x) and philanthropic funding bodies (8x) and an Award from the University of Melbourne.

Funding Summary

Number of grants

6

Total funding

$880,020

Projects

Gaining new insights into metastatic bone tumours (2020)$24,925
Description
Molecular analysis of prostate cancer tumour specimen to identify new molecular targets for therapy.
Funding
Royal Hobart Hospital Research Foundation ($24,925)
Scheme
Grant-Project
Administered By
University of Tasmania
Research Team
Dickinson JL; Holloway AF; Nott LM; Liu G; Fitzgerald LM; Brettingham-Moore KH; Hewitt A; Taberlay PC
Year
2020
Losing the needle: Using eye drop-based switchable gene therapy as a non-invasive controlled intervention in neovascular blindness (2020 - 2022)$683,290
Description
Neovascularisation and vascular hyperpermeability are common and potentially devastating complications of neovascular eye diseases, including age-relatedmacular degeneration and diabetic retinopathy. Regular intraocular injections of a medication (monoclonal antibodies, antibody fragments and antibodyreceptorfusion proteins) that blocks a disease-causing mediator, Vascular endothelial growth factor (VEGF), is highly effective at treating these neovasculareye diseases. However, the treatment requires frequent injections over a long period of time, is difficult for patients and their families and poses a largeburden on health systems. We have developed a new approach of gene therapy that blocks VEGF by an intercellular VEGF decoy receptor in the eye for aprolonged period using a single injection. Our approach differs from other gene therapy as we can effectively tailor the effect of the eye treatment with ananocarrier-based eye drop. Our approach will overcome the need for repeated injection, as it will allow sustained-tailored therapy. This is a ground-breakingapproach that has not been attempted with any current published ocular gene therapy work. By doing so we will develop a safer, more convenient andeffective treatments to prevent vision loss in neovascular eye diseases. This project will fundamentally change the long-term management of neovascular eyedisease and has significant economic benefits in Australia and worldwide
Funding
National Health & Medical Research Council ($683,290)
Scheme
Grant-Ideas
Administered By
University of Tasmania
Research Team
Liu G; Wong V
Period
2020 - 2022
Grant Reference
1185600
Switchable Gene Therapy for Controlled Intervention in Neovascular Blindness (2019)$49,920
Description
Eye disease is a common and potentially devastating complication of diabetes. We have developed a new method of blocking disease-causing chemical (VEGF) in the eye for a prolonged period and the effect of the eye treatment can be tailored via an oral tablet. While we are in the early stages of testing our approach, we expect it to be safer, more convenient and possibly more effective than current treatments, leading to better outcomes for people with diabetes.
Funding
Ophthalmic Research Institute of Australia ($49,920)
Scheme
Grant-Research
Administered By
University of Tasmania
Research Team
Liu G; Bui B
Year
2019
Targeting dysregulated miRNAs and transforming growth factor-B-activated kinase 1 (TAK1) to stop the growth of leaky blood vessels in diabetic eyes (2018)$24,540
Description
Vision loss from diabetic retinopathy is a global clinical and public health concern, significantlyimpacting the quality of life of patients. Whilst therapies such as anti-VEGF (antibody-basedmedications) have been a breakthrough in the management of vision-threatening stages ofdiabetic retinopathy, significant irreversible retinal damage can already have occurred by thisstage. Here we seek support to develop the novel therapeutic strategies targeting critical generegulator (microRNAs, short non-coding RNAs), that combat the earliest pathological cascadesthat predispose to blindness in those with diabetes. Success in this project will provide theimpetus to pursue novel treatments that target the earliest pathological steps in the developmentof diabetic retinopathy. This has important implications for preventing vision loss in asubstantial number of people at risk from diabetic retinopathy.
Funding
University of Tasmania ($24,540)
Scheme
Grant- Research Enhancement Program
Administered By
University of Tasmania
Research Team
Liu G; Bui B; Leung JY; Dusting G
Year
2018
CRISPR screen to identify key genes driving DFTD (2017)$33,500
Description
We will apply leading genomic techniques to identify the genes essential for the proliferation of the Tasmanian Devil Facial Tumour. By systematically disrupting each gene in the cancer, we will also identify genes which help the tumour evade the immune system.
Funding
University of Tasmania Foundation Inc ($33,500)
Scheme
Grant-Dr Eric Guiler Tasmanian Devil Research Gran
Administered By
University of Tasmania
Research Team
Hewitt A; Liu G; Woods GM; Flies AS; Cook AL
Year
2017
Developing CRISPR/Cas Library Screens for identifying Novel Cancer Therapies (2017)$63,845
Description
Our understanding of many cancers has improved dramatically over the past decade predominantly due to our ability to sequence entire genomes, at scale. Yet, we still require a better understanding of the underlying mechanisms that initiate and perpetuate cancers, as well as gene-based factors that initiate the transition from indolent to aggressive cancers with a propensity to metastasize. CRISPR/Cas is proving a robust, powerful and necessary tool in the laboratory that will undoubtedly underpin the next breakthrough in the field of cancer. As such, it is essential that we develop this capability at the University of Tasmania in a timely manner.The specific AIMS of this proposal are to:Aim 1: Establish CRISPR/Cas screening at the University of Tasmania as a tool to identify genesthat drive aggressive and metastatic cancers.Aim 2: Perform a genome-wide CRISPR/Cas negative selection (loss-of-function) screen toidentify genes essential for proliferation and survival, as well as metastatic behaviour.
Funding
University of Tasmania Foundation Inc ($63,845)
Scheme
Grant-Cancer Research
Administered By
University of Tasmania
Research Team
Taberlay PC; Hewitt A; Holloway AF; Liu G; Dickinson JL; Brettingham-Moore KH; Fitzgerald L; Eri RD; Cook AL
Year
2017

Research Supervision

The research team currently led by Dr Liu comprising of 2 postdoc fellows and 4 PhD students (1 as a principal supervisor). To date, he has supervised the completion of 2 PhD, 4 masters and 2 honours students (all as principal supervisor). He has also been mentoring 3 postdoc fellows and a research assistant in last 5 years.

Current

6

Current

DegreeTitleCommenced
PhDDevelopment of CRISPR/Cas-Mediated Gene Editing in the Retina2018
PhDCRISPR/Cas-Base Editing Applications for Eye Disease2018
PhDGenome-Wide Analysis Of Gene Regulatory Networks In Primary Open Angle Glaucoma2018
PhDFunctional Evaluation of Mutations in HTR1F and Other Paediatric Cataract Genes2019
PhDTranslation of Glaucoma Blindness Genes to Improve Clinical Practice2019
PhDIdentifying the Role of Inflammatory Circuit in Establishing and Pathogenesis of Colon Cancer2019